The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multiparameter classifier to predict response to lapatinib plus trastuzumab (LT) without chemotherapy in HER2+ breast cancer (BC).
 
Jamunarani Veeraraghavan
No Relationships to Disclose
 
Carolina Gutierrez
Research Funding - Ventana Medical Systems
 
Carmine De Angelis
Consulting or Advisory Role - Roche
Speakers' Bureau - Lilly; Novartis; Pfizer
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Tao Wang
No Relationships to Disclose
 
Tomás Pascual
Consulting or Advisory Role - Roche/Genentech
Research Funding - MSD Oncology (Inst); Roche/Genentech (Inst)
 
Britta Weigelt
Consulting or Advisory Role - Genentech/Roche (I); Goldman Sachs (I); Invicro (I); PAIGE (I); Repare Therapeutics (I); Repare Therapeutics (I); Ventana Medical Systems (I); Volition RX (I)
 
Patricia Galvan
No Relationships to Disclose
 
Brent Neil Rexer
Research Funding - Daiichi Sankyo (Inst)
 
Andres Forero-Torres
Employment - Seagen
Stock and Other Ownership Interests - Seagen
Speakers' Bureau - Seagen
Research Funding - Daiichi Sankyo (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Novartis (Inst); Oncothyreon (Inst); Pfizer (Inst); Seagen (Inst); Syndax (Inst); TRACON Pharma (Inst)
 
Antonio C. Wolff
Consulting or Advisory Role - Ionis Pharmaceuticals
Research Funding - Biomarin (Inst); Celldex (Inst)
Patents, Royalties, Other Intellectual Property - Antonio Wolff has been named as inventor on one or more issued patents or pending patent applications relating to methylation in breast cancer, and has assigned his rights to JHU, and participates in a royalty sharing agreement with JHU.
 
Rita Nanda
Consulting or Advisory Role - Aduro Biotech; Athenex; Daiichi Sankyo; Genentech/Roche; ION Pharma; Macrogenics; Merck; Pfizer; Seagen
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Celgene (Inst); Corcept Therapeutics (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Merck (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Seagen (Inst)
Other Relationship - G1 Therapeutics
 
Anna Maria Storniolo
Employment - Boston Pharmaceuticals (I); Sophren Therapeutics (I)
Leadership - Boston Pharmaceuticals (I); Sophren Therapeutics (I)
Stock and Other Ownership Interests - Gilead Sciences; Inovio Pharmaceuticals (I); Lilly (I); Merck
Consulting or Advisory Role - AdMirX (I); Atlas Venture (I); Boston Pharmaceuticals (I); Deerfield Management (I); ResoTher (I); Sophren Therapeutics (I)
Research Funding - Que Pharma
 
Ian E. Krop
Consulting or Advisory Role - Context Therapeutics; Daiichi Sankyo; Macrogenics; Taiho Pharmaceutical
Research Funding - Genentech (Inst); Pfizer (Inst); Roche (Inst)
 
Matthew P. Goetz
Consulting or Advisory Role - bioTheranostics; Context Therapeutics; Eisai; Genomic Health; Lilly; Novartis; Pfizer; Sermonix Pharmaceuticals
Research Funding - Lilly; Pfizer
Patents, Royalties, Other Intellectual Property - Development of Human Tumor Xenografts from Women with Breast Cancer Treated with Neoadjuvant Chemotherapy (Inst); Methods and Materials for Assessing Chemotherapy Responsiveness and Treating Cancer; METHODS AND MATERIALS FOR USING BUTYRYLCHOLINESTERASES TO TREAT CANCER
Travel, Accommodations, Expenses - Lilly
 
Jorge S. Reis-Filho
Consulting or Advisory Role - Genentech/Roche; Goldman Sachs; Invicro; Novartis; Paige.AI; Repare Therapeutics; Ventana Medical Systems; Volition RX
 
Susan G. Hilsenbeck
No Relationships to Disclose
 
Aleix Prat
Employment - Novartis (I)
Honoraria - Amgen; Daiichi Sankyo; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - Abbvie; Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Daiichi Sankyo; NanoString Technologies (Inst); Novartis; Oncolytics; Pfizer; Puma Biotechnology; Roche
Research Funding - Incyte (Inst); Novartis (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - PCT/EP2016/080056: HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY; WO/2018/096191. Chemoendocrine score (CES) Based on PAM50 for breast cancer with positive hormone receptors with an intermediate risk of recurrence
Travel, Accommodations, Expenses - Daiichi Sankyo
Other Relationship - Oncolytics; Peptomyc
 
C. Kent Osborne
Stock and Other Ownership Interests - Genetex
Consulting or Advisory Role - AstraZeneca; Genentech; Lilly; Tolmar
 
Rachel Schiff
Consulting or Advisory Role - Macrogenics
Research Funding - AstraZeneca; Gilead Sciences; Puma Biotechnology
Patents, Royalties, Other Intellectual Property - Wolters Kluwer
 
Mothaffar F. Rimawi
Consulting or Advisory Role - Daiichi Sankyo; Genentech; Macrogenics; Novartis
Research Funding - Pfizer (Inst)